By Adam Rhodes ( September 26, 2018, 7:23 PM EDT) -- Boston-based biopharmaceutical company Alexion Pharmaceuticals Inc. has agreed to buy venture capital-backed Syntimmune in an up to $1.2 billion deal guided by Foley Hoag LLP, Goodwin Procter LLP and Sullivan & Cromwell LLP, the companies said Wednesday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.